Eurobio Scientific stock surges over 23% following its mandatory buyback offer project
The shares of the biological diagnostics distributor are soaring during the session, driven by the announcement of a mandatory buyback offer project formulated by its majority shareholder. The price is approaching the offer price proposed by EB Development, just days before a half-yearly publication that will serve as the official filing point for the operation.
A buyback offer project at €25.30 per share that propels the stock toward its target price
The Eurobio Scientific stock gains 23.53% during the session, at €25.20, following the announcement published on September 16 of a mandatory buyback offer project at €25.30 per share, representing a premium of 26% over the previous day's closing price (€20.40). The initiator is EB Development, which already controls 90.14% of the capital. The stock is therefore trading less than 0.40% below the proposed price, reflecting the market's near-certainty of the operation's completion.
The mandatory buyback offer procedure, characteristic of companies with very limited free float, generally aims to allow remaining minority shareholders to exit at a guaranteed price before a potential delisting. EB Development plans to formally file its project upon the publication of half-yearly results, expected on September 24, 2026.
A rebound that repositions the stock well above its moving averages in a market globally oriented upward
Mechanically, the session's surge repositions the stock significantly above its three moving averages: the 20-day MA stands at €20.01, the 50-day MA at €20.62, and the 200-day MA at €22.47, representing respective gaps of approximately 26%, 22%, and 12% below the current price. The RSI at 52 remains in neutral territory, far from any overbought configuration, which is explained by the event-driven nature of the movement rather than gradual speculative momentum. Over the week, the stock shows a gain of 25.81%, and over three months, the increase reaches 11.56%.
The technical resistance identified at €25.55 is situated less than one percent above the current price, but in the context of a mandatory buyback offer at €25.30, it is this reference price that structures trading. The next milestone is the publication of half-yearly results for the period ended June 30, 2026, scheduled for September 24, 2026, on which occasion the buyback offer project must be formally filed.
